Court Blocks Israeli Co. From Suing Amgen

Law360, New York (January 30, 2007, 12:00 AM EST) -- Notching a win for Amgen Inc. in a protracted patent dispute over its arthritis drug Enbrel, a U.S. federal appeals court has found that an Israeli company cannot collect royalties on the treatment.

The U.S. Court of Appeals for the Federal Circuit ruled Monday that Israel Bio-Engineering Project (IBEP) did not have standing to bring a patent infringement suit against Amgen because it could not pin down the sole ownership of the patent.

On the surface, the disagreement involved a protein used to remedy rheumatoid arthritis...
To view the full article, register now.